Q-Line Biotech NSE SME IPO review

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
As the company has no listed peers, it is trying to extract fancy price for its IPO.
Based on its overall financial data, the issue appears fully priced.
Well-informed investors may park moderate funds for long term.

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges.

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies.

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share. The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes.

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr.

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained.

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended	Revenue	Expense	PAT	Assets
2023	₹184.81	₹154.97	₹32.10	₹251.58
2024	₹206.45	₹175.85	₹34.44	₹339.25
2025	₹322.58	₹261.43	₹28.13	₹455.49
Dec 2025	₹236.50	₹186.96	₹38.69	₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company	Face Value (₹)	EPS basic (₹)	EPS Diluted (₹)	RONW (%)	P/E Ratio	NAV (₹)
Powerica Limited	5	15.26	15.26	15.37 %	24.45	99.76
Listed Peers
Cummins India Limited	2	72.15	72.15	26.45%	64.13	272.78
Kirloskar Oil Engines Limited	2	33.71	33.60	15.85%	43.24	212.60
NTPC Green Energy Limited	10	0.67	0.67	2.58%	129.40	21.88
Acme Solar Holdings Limited	2	4.55	4.53	5.59%	50.74	74.54
Adani Green Energy Limited	10	8.37	8.37	11.90%	101.53	76.62

Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion

Q-Line Biotech IPO FAQs

1. What is Q-Line Biotech IPO? ⌄

Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.

2. When Q-Line Biotech IPO will open for subscription? ⌄

The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.

3. What is Q-Line Biotech IPO Investors Portion? ⌄

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

4. How to Apply the Q-Line Biotech IPO? ⌄

You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

5. What is Q-Line Biotech IPO Issue Size? ⌄

Q-Line Biotech IPO issue size is ₹214 crores.

6. What is Q-Line Biotech IPO Price Band? ⌄

Q-Line Biotech IPO Price Band is ₹326 to ₹343.

7. What is Q-Line Biotech IPO Lot Size? ⌄

The minimum bid is 800 Shares with ₹2,74,400 amount.

8. What is the Q-Line Biotech IPO Allotment Date? ⌄

Q-Line Biotech IPO allotment date is May 26,2026.

9. What is the Q-Line Biotech IPO Listing Date? ⌄

Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

HDB Financial IPO Date, Review, Price, Allotment Details

By Jagat Joshi
June 28, 2025

HDB Financial IPO open date is June 25, 2025 and the IPO will close on June 27, 2025. HDB Financial IPO is a Book Built Issue. The company to raise around ₹12,500 crores via IPO that comprises fresh issue of ₹2,500 crores and offer for sale up to 13,51,35,135 equity shares with face value of ₹10 each.

HDB Financial IPO price band is ₹700 to ₹740 per share. The retail quota is 35%, QIB is 50%, and HNI is 15%. HDB Financial IPO to list on BSE, NSE on July 2, 2025. The allotment of HDB Financial IPO date is June 30, 2025.

The company reported revenue of ₹16,300.28 crores in 2025 against ₹14,171.12 crore in 2024. The company reported profit of ₹2,175.92 crores in 2025 against profit of ₹2,460.84 crores in 2024. As per the financials the IPO investors should apply the IPO for a long term.

HDB Financial IPO Details

IPO Open Date:	June 25, 2025
IPO Close Date:	June 27, 2025
Face Value:	₹10 Per Equity Share
IPO Price Band:	₹700 to ₹740 Per Share
Issue Size:	Approx 12,500 Crores
Fresh Issue:	Approx ₹2,500 Crores
Offer for Sale:	Approx 13,51,35,135 Equity Shares
Issue Type:	Book Built Issue
IPO Listing:	BSE & NSE
Retail Quota:	Not more than 35%
QIB Quota:	Not more than 50%
NII Quota:	Not more than 15%
DRHP Draft Prospectus:	Click Here
RHP Draft Prospectus:	Click Here
Anchor Investors List:	Click Here

HDB Financial IPO Market Lot

The HDB Financial IPO minimum market lot is 20 shares with ₹14,800 application amount. The retail investors can apply up-to 13 lots with 260 shares of ₹1,92,400 amount.

Application	Lot Size	Shares	Amount
Retail Minimum	1	20	₹14,800
Retail Maximum	13	260	₹1,92,400
S-HNI Minimum	14	280	₹2,07,200
B-HNI Minimum	68	1,360	₹10,06,400

HDB Financial IPO Dates

The HDB Financial IPO date is June 25 and the close date is June 27. The HDB Financial IPO allotment will be finalized on June 30 and the IPO listing on July 2.

IPO Open Date:	June 25, 2025
IPO Close Date:	June 27, 2025
Basis of Allotment:	June 30, 2025
Refunds:	July 1, 2025
Credit to Demat Account:	July 1, 2025
IPO Listing Date:	July 2, 2025

Promoters of HDB Financial IPO

The promoters of the company is HDFC Bank Limited.

About HDB Financial IPO

HDB Financial Services began its journey in 2007 and is one of the growing diversified retail-focused non-banking financial Upper-Layer companies (NBFCs) in India. The company’s portfolio consists of a diverse range of lending products throughout 3 major areas that is Enterprise Lending, Asset Finance, and Consumer Finance. The company serves its services, especially to salaried, self-employed customers, along with business owners and entrepreneurs. Their goal is to provide financial services to underserved and underbank customers who come from low to middle-class families who have little to no credit history. HDB Financial is one of the largest growing customer franchises in India catering to 17.5 million customers. They are committed to meeting the requirements of its wide range of customers by offering excellent customer service and a diverse range of products with fast-driven technology. Currently, they have a network of 1,772 branches in 1,162 towns across 31 States and Union Territories across India.

HDB Financial IPO Company Financial Report

The company reported revenue of ₹16,300.28 crores in 2025 against ₹14,171.12 crore in 2024. The company reported profit of ₹2,175.92 crores in 2025 against profit of ₹2,460.84 crores in 2024.

Amount ₹ in Crores

Period Ended	Revenue	Expense	Profit After Tax	Assets
2022	₹11,306.29	₹9,958.73	₹1,011.40	₹62,025.94
2023	₹12,402.88	₹9,775.48	₹1,959.35	₹70,050.39
2024	₹14,171.12	₹10,866.45	₹2,460.84	₹92,556.51
2025	₹16,300.28	₹13,372.48	₹2,175.92	₹1,08,663.29

HDB Financial IPO Valuation – FY2025

Check HDB Financial IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.

KPI	Values
ROE:	14.72%
ROCE:	[.]%
EBITDA Margin:	[.]%
PAT Margin:	[.]%
Debt to equity ratio:	5.85
Earning Per Share (EPS):	₹27.4 (Basic)
Price/Earning P/E Ratio:	N/A
Return on Net Worth (RoNW):	14.7%
Net Asset Value (NAV):	₹198.8

Peer Group Comparison

Company	EPS	PE Ratio	RoNW %	NAV	Income
Bajaj Finance Limited	26.89	34.3	19.35%	155.6	69,683.51Cr.
Sundaram Finance Limited	170.53	28.1	15.48%	1,187.8	8,485.63 Cr.
L&T Finance Limited	10.61	17.9	10.79%	102.5	15,924.24Cr.
Mahindra & Mahindra Financial Services Limited	18.32	14.5	10.91%	154.9	18,463.10Cr.
Cholamandalam Investment and Finance Company Limited	50.72	31.4	19.71%	281.5	25,845.98Cr.
Shriram Finance Limited	50.82	13.0	18.17%	300.3	41,834.42Cr.

Objects of the Issue

Augmentation of the Company’s Tier – I Capital base to meet their Company’s future capital requirements including onward lending under any of the Company’s business verticals i.e. Enterprise Lending, Asset Finance and Consumer Finance.

HDB Financial IPO Review

IPO Watch – May Apply
Canara Bank –
DRChoksey FinServ –
Emkay Global –
Hem Securities –
IDBI Capital –
Marwadi Shares –
Nirmal Bang –
SBICAP Securities –
Sharekhan –
SMC Global –
Sushil Finance –
Swastika Investmart –
Ventura Securities –
Geojit –
Reliance Securities –
Capital Market –
BP Wealth –
ICICIdirect –
Choice Broking –

HDB Financial IPO Registrar

MUFG Intime India Private Limited
Phone: +91 810 811 4949
E-mail: hdbfinancial.ipo@linkintime.co.in
Website: https://in.mpms.mufg.com/Initial_Offer/public-issues.html

IPO Lead Managers aka Merchant Bankers

JM Financial Limited
BNP Paribas
BofA Securities India Limited
Goldman Sachs (India) Securities Private Limited
HSBC Securities and Capital Markets (India) Private Limited
IIFL Securities Limited
Jefferies India Private Limited
Morgan Stanley India Company Private Limited
Motilal Oswal Investment Advisors Limited
Nomura Financial Advisory and Securities (India) Private Limited
Nuvama Wealth Management Limited
UBS Securities India Private Limited

Company Address

HDB Financial Services Limited
HDB House, Tukaram
Sandam Marg, ASubhash Road,
Vile Parle (East),
Mumbai – 400057,
Maharashtra, India
Phone: +91 22 4911 6350
E-mail: investorcommunications@hdbfs.com
Website: www.hdbfs.com

HDB Financial IPO FAQs

What is HDB Financial IPO?

HDB Financial IPO is a Mainboard IPO. The company is going to raise ₹12,500 Crores via IPO. The issue is priced at ₹700 to ₹740 per equity share. The IPO is to be listed on BSE & NSE.

When HDB Financial IPO will open for subscription?

The IPO is to open on June 25, 2025 for QIB, NII, and Retail Investors. The IPO will close on June 27, 2025.

What is HDB Financial IPO Investors Portion?

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

How to Apply the HDB Financial IPO?

You can apply for HDB Financial IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

What is HDB Financial IPO Issue Size?

HDB Financial IPO issue size is ₹12,500 crores.

What is HDB Financial IPO Price Band?

HDB Financial IPO Price Band is ₹700 to ₹740.

What is HDB Financial IPO Lot Size?

The minimum bid is 20 Shares with ₹14,800 amount.

What is the HDB Financial IPO Allotment Date?

HDB Financial IPO allotment date is June 30, 2025.

What is the HDB Financial IPO Listing Date?

HDB Financial IPO listing date is July 2, 2025. The IPO is to list on BSE & NSE.

Note: The HDB Financial IPO price band and date are officially announced. The (HDB Financial IPO grey market premium) will be added to the IPO GMP page as it will start).

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.